Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Herz
Erschienen in: Herz 2/2019

07.03.2019 | Herzinsuffizienz | CME

Krebserkrankungen heilen und das Herz schützen

Herausforderungen der Kardioonkologie im Zeitalter moderner Tumortherapien

verfasst von: C. Hohmann, S. Baldus, Prof. Dr. med. R. Pfister

Erschienen in: Herz | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Fortschritte der medikamentösen onkologischen Behandlungsmöglichkeiten haben in den vergangenen Jahren zu einer deutlichen Verbesserung der Überlebensrate bei Krebserkrankungen geführt. Bei vielen der neu entwickelten medikamentösen Behandlungsansätze bestehen jedoch direkte oder indirekte Effekte auf das kardiovaskuläre System. Kardiovaskuläre Erkrankungen stellen bereits jetzt die häufigste nicht malignomassoziierte Todesursache bei Tumorpatienten dar. Prävention, frühzeitiges Erkennen dieser Komplikationen, richtiges Management und zeitnaher Beginn einer spezifischen kardialen medikamentösen Therapie bilden die Schüssel für eine Verbesserung der kardiovaskulären Prognose. Dieser Artikel gibt eine Übersicht über die möglichen kardiotoxischen Nebenwirkungen wichtiger onkologischer Therapien und erläutert praxisnah mögliche Strategien hinsichtlich Risikostratifikation, kardiologischer Nachsorge sowie Behandlungsansätze einer chemotherapieinduzierten linksventrikulären Dysfunktion.
Literatur
1.
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:359–368CrossRef
2.
Bui AL, Horwich TB, Fonarow GC (2011) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8:30–41CrossRef
3.
Riley JP, Beattie JM (2017) Palliative care in heart failure: facts and numbers. Esc Heart Fail 4:81–81CrossRef
4.
Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 8:175–179CrossRef
5.
Springer J, Springer JI, Anker SD (2017) Muscle waisting and sarcopenia in heart failure and beyond: update 2017. ESC Heart Fail 4:492–498CrossRef
6.
Saitoh M, Dos SMR, Emami A et al (2017) Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). ESC Heart Fail 4:448–457CrossRef
7.
von Haeling S (2017) Co-morbidities in heart failure beginning to sprout-and no end in sight? Eur J Heart Fail 19:1566–1568CrossRef
8.
Zamorano JL, Lancellotti P, Rodriguez Munoz D et al (2017) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 19:9–42CrossRef
9.
Bhatnagar P, Wickramasinghe K, Williams J et al (2015) The epidemiology of cardiovascular disease in the UK 2014. Heart 101:1182–1189CrossRef
10.
Brown BW, Brauner C, Minnotte MC (1993) Noncancer deaths in white adult cancer patients. J Natl Cancer Inst 85:979–987CrossRef
11.
Chauhan A, Burkeen G, Houranieh J et al (2017) Immune checkpoint-associated cardiotoxicity: Case report with systematic review of literature. Ann Oncol 28(8):2034–2038CrossRef
12.
Shanafelt TD, Parikh SA, Noseworthy PA et al (2017) Atrial fibrillation in patients with chronic lymphotic leukemia (CLL). Leuk Lymphoma 58:1630–1639CrossRef
13.
DeSantis C, Lin C, Mariotto A et al (2014) Cancer treatment and survivorship statistics. CA Cancer J Clin 64:252–271CrossRef
14.
Truong J, Yan AT, Cramarossa G et al (2014) Chemotherapy-induced cardiotoxicity: detection, prevention and management. Can J Cardiol 30:869–878CrossRef
15.
Lenihan D, Cardinale D (2012) Late cardiac effects on cancer treatment. J Clin Oncol 30:3657–3664CrossRef
16.
Yeh ETH, Bickford CL (2009) Cardiovascular complications of cancer therapy. Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231–2247CrossRef
17.
Hahn VS, Lenihan DJ, Ky B (2014) Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc 3(2):e665CrossRef
18.
Cardinale D, Colombo A, Bacchiani G et al (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981–1988CrossRef
19.
Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47–58CrossRef
20.
Lotrionte M, Biondi-Zoccai G, Abbate A et al (2013) Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 112:1980–1984CrossRef
21.
Yeh ETH (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109:3122–3131CrossRef
22.
Felker GM, Thompson RE, Hare JM et al (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077–1084CrossRef
23.
von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717CrossRef
24.
Ewer MS, Ewer SM (2015) Cardiotoxicity of anti-cancer treatments. Nat Rev Cardiol 12:547–558CrossRef
25.
Minotti G, Menna P, Salvatorelli E et al (2004) Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229CrossRef
26.
Rafiyath SM, Rasul M, Lee B et al (2012) Comparison of safety and toxicity of liposomal doxorubicin versus conventional anthracyclines: a meta-analysis. Exp Hematol Oncol 1:10CrossRef
27.
28.
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:183–792CrossRef
29.
Payne DL, Nohria A (2017) Prevention of chemotherapy induced cardiomyopathy. Curr Heart Fail Rep 14(5):398–403CrossRef
30.
Moslehi JJ (2016) Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375:1457–1467CrossRef
31.
Eschenhagen T, Force T, Ewer M et al (2011) Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 13:1–10CrossRef
32.
Telli ML, Hunt SA, Carlson RW et al (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25(23):3252–3533CrossRef
33.
Ponde NF, Lambertini M, de Azambuja E (2016) Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open 1:e73CrossRef
34.
Ghatalia P, Je Y, Kaymakcalan MD et al (2015) QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 112:296–305CrossRef
35.
Small HY, Montezano AC, Rios FJ et al (2014) Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol 30:534–543CrossRef
36.
Hall PS, Harshman LC, Srinivas S et al (2013) The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail 1:72–78CrossRef
37.
Robinson ES, Matulonis UA, Ivy P et al (2010) Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol 5:477–483CrossRef
38.
Rini BI, Cohen DP, Lu DR et al (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763–773CrossRef
39.
Narayan V, Keefe S, Haas N et al (2017) Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma. Clin Cancer Res 23:3601–3609CrossRef
40.
Thomas A, Hassan R (2012) Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 13:e301–e310CrossRef
41.
Moslehi JJ, Salem JE, Sosman JA et al (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391:933CrossRef
42.
Heinzerling L, Ott PA, Hodi FS et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50CrossRef
43.
Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749–1755CrossRef
44.
Escudier M, Cautela J, Malissen N et al (2017) Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136:2085–2087CrossRef
45.
Mahmood SS, Nohria A (2016) Cardiovascular complications of cranial and neck radiation. Curr Treat Options Cardiovasc Med 18:45CrossRef
46.
Bloom MW, Hamo CE, Cardinale D (2016) Cancer therapy-related cardiac dysfunction and heart failure: Part 1: Definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail 9:e2661CrossRef
47.
Ullrich NJ, Robertson R, Kinnamon DD et al (2007) Moyamoya following cranial irradiation for primary brain tumors in children. Baillieres Clin Neurol 68:932–938
48.
Armanious MA, Mohammadi H, Khodor S et al (2018) Cardiovascular effects of radiation therapy. Curr Probl Cancer 42(4):433–442CrossRef
49.
Lenneman CG, Cardio-oncology SDB (2016) An update on cardiotoxicity of cancer-related treatment. Circ Res 118:1008–1020CrossRef
50.
Rochette L, Guenancia C, Gudjoncik A et al (2015) Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci 36:326–348CrossRef
51.
Mushlin PS, Cusack BJ, Boucek RJ Jr et al (1993) Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 110:975–982CrossRef
52.
Zhang S, Liu X, Bawa-Khalfe T et al (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18:1639–1642CrossRef
53.
Ewer MS, Vooletich MT, Durand JB et al (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clinoncol 23:7820–7826CrossRef
54.
De Keulenaer GW, Doggen K, Lemmens K (2010) The vulnerability the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 106:35–46CrossRef
55.
Telli ML, Hunt SA, Carlson RW et al (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clinoncol 25:3525–3533CrossRef
56.
Lichtman AH (2013) The heart of the matter: protection of the myocardium from T cells. J Autoimmun 45:90–96CrossRef
57.
Tarrio ML, Grabie N, Bu DX et al (2012) PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 188:4876–4884CrossRef
58.
Gröschel C, Sasse A, Röhrborn C et al (2017) T helper cells with specificity for an antigen in cardiomyocytes promote pressure overload-induced progression from hypertrophy to heart failure. Sci Rep 7:15998CrossRef
59.
Thavendiranathan P, Grant AD, Negishi T et al (2013) Reproducibility echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 61:77–84CrossRef
60.
Krischer JP, Epstein S, Cuthbertson DD et al (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 15:1544–1552CrossRef
61.
Linschoten M, Teske AJ, Cramer MJ et al (2018) Chemotherapy-related cardiac dysfunction—a systematic review of genetic variants modulating individual risk. Circ Genom Precis 11:e1753
62.
Dranitsaris G, Rayson D, Vincent M et al (2008) The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat 107:443–450CrossRef
63.
Ezaz G, Long JB, Gross CP et al (2014) Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 3:e472CrossRef
64.
Armenian SH, Hudson MM, Mulder RL et al (2015) Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16:e123–e136CrossRef
65.
Vejpongsa P, Yeh ET (2014) Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 64:938–945CrossRef
66.
Slingerland M, Guchelaar HJ, Gelderblom H (2012) Lipsomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 17:160–166CrossRef
67.
Plana JC, Galderisi M, Barac A et al (2014) Expert Consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 10:1063–1093CrossRef
68.
Jones AL, Barlow M, Barrett-Lee PJ et al (2009) Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 100:684–692CrossRef
Metadaten
Titel
Krebserkrankungen heilen und das Herz schützen
Herausforderungen der Kardioonkologie im Zeitalter moderner Tumortherapien
verfasst von
C. Hohmann
S. Baldus
Prof. Dr. med. R. Pfister
Publikationsdatum
07.03.2019
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe 2/2019
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-019-4787-6

Weitere Artikel der Ausgabe 2/2019

Herz 2/2019 Zur Ausgabe

Original articles

Vitamin D deficiency and functional response to CRT in heart failure patients

Original articles

Impact of right ventricular diastolic dysfunction on clinical outcomes in inferior STEMI

Main topic

Key inflammatory pathways underlying vascular remodeling in pulmonary hypertension

Main topic

Key inflammatory mechanisms underlying heart failure

Main topic

Inflammation in thoracic aortic aneurysms

Main topic

Critical inflammatory mechanisms underlying arrhythmias

Weitere Lesetipps

ANZEIGE

Spektrum Dermatologie: Jetzt auch auf medbee – die App für Mediziner*innen

Rechtssichere Aufklärung in der Medizin

Sind Sie heute schon versetzt worden?

Krebspatientin unter "Chemo" geht es plötzlich schlechter

ANZEIGE

Weißer Hautkrebs verursacht mehr Tote als das Melanom

ANZEIGE

Dexpanthenol verstärkt die positiven Effekte der LASH-Methode

Bildnachweise